Coral Laboratories Ltd. – Company Report
1. Company Overview
Coral Laboratories Ltd., established in 1994 and headquartered in Mumbai, Maharashtra, is an Indian pharmaceutical manufacturer engaged in the development, production, and export of pharmaceutical formulations. The company operates certified manufacturing facilities at multiple locations across India, producing a wide range of products for both domestic and global markets. Coral Laboratories emphasizes ethical compliance, high-quality standards (ISO 9001:2008 certified), and a philosophy built on integrity and core values. The company is nearly debt-free, with a track record of prudent financial management and steady growth over two decades.
- Incorporated: 1994
- Headquarters: Mumbai, Maharashtra, India
- Certifications: ISO 9001:2008; WHO-GMP compliant
- Core Focus: Pharmaceutical formulations—tablets, capsules, liquids, topicals
- Market Capitalization (July 2025): ~₹211 crore
- Directors: Includes Sheela Rupesh Kamdar, Saurabh Kamlesh Shah, and others
- Global Reach: Manufacturing and exports to more than 15 countries
2. Products and Services
Coral Laboratories Ltd. delivers a broad portfolio of pharmaceutical formulations addressing key therapeutic segments:
Product Categories:
- Tablets, hard and soft gelatin capsules
- Oral liquids (syrups and suspensions)
- Ointments and topical creams/gels
- Products tailored for anti-infective, cardiovascular, anti-diabetic, gastrointestinal, and pain management applications
Manufacturing & Quality:
- Manufacturing units in Dehradun (Uttarakhand) and Daman and Diu
- Advanced granulation, blister packaging, automated filling, and quality control laboratories
- Compliant with Indian and global regulatory requirements
Contract Manufacturing & Exports:
- Private label and contract manufacturing for Indian and international brands
- Active export base with focus on Africa, CIS countries, Southeast Asia, and LATAM markets
Coral has a reputation for flexible production capabilities and customized solutions for clients, with a stable reputation among public and private sector buyers.
3. Recent News and Financial Performance
Recent News and Developments
- As of July 2025, Coral Laboratories’ board approved its audited financials for the year ended March 2025 and recommended a final dividend to shareholders for FY2025.
- The company also announced new appointments in internal, secretarial, and cost audit roles for the coming fiscal year.
- Operational updates include ongoing board meetings to ensure regulatory compliance.
- No major litigation or adverse regulatory actions have been reported recently.
4. Financial Performance
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue from Operations | ₹115 crore | ₹84 crore |
| Net Profit | ₹24 crore | ₹16 crore |
| Operating Profit Margin (OPM) | 23% | — |
| Earnings Per Share (EPS) | ₹67.63 | — |
| Return on Equity (ROE) | 13.1% | — |
| Dividend per Share | ₹2.00 | — |